Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

3.0K
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR...
3.0K
T Cell Activation and Clonal Selection01:22

T Cell Activation and Clonal Selection

17.8K
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
17.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Phase I trial of daily subcutaneous SPL-108 injections in combination with paclitaxel in patients with platinum resistant CD44+ advanced ovarian epithelial cancer.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2022
Same author

A6 peptide activates CD44 adhesive activity, induces FAK and MEK phosphorylation, and inhibits the migration and metastasis of CD44-expressing cells.

Molecular cancer therapeutics·2011
See all related articles

Related Experiment Video

Updated: Apr 15, 2026

Use of Single Chain MHC Technology to Investigate Co-agonism in Human CD8+ T Cell Activation
12:09

Use of Single Chain MHC Technology to Investigate Co-agonism in Human CD8+ T Cell Activation

Published on: February 28, 2019

10.4K

Modulation of CD44 Activity by A6-Peptide.

Malcolm Finlayson1

  • 1Ångstrom Pharmaceuticals Inc. , Solana Beach, CA , USA.

Frontiers in Immunology
|April 15, 2015
PubMed
Summary

The peptide A6 targets CD44, inhibiting cancer cell migration and metastasis. It shows promise in treating various diseases, including cancer and eye conditions, with a strong safety profile.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Oncology

Background:

  • Hyaluronan (HA) is crucial in the extracellular matrix, influencing cell behavior.
  • CD44 is a cell surface receptor for HA, mediating cell signaling and disease progression.
  • CD44 activation by HA promotes cancer cell survival.

Purpose of the Study:

  • To review the therapeutic potential of peptide A6.
  • To discuss A6's modulation of hyaluronan (HA) and CD44 interactions.
  • To explore A6 as a novel therapeutic strategy.

Main Methods:

  • A6 peptide characterization and binding assays.
  • In vitro and in vivo studies on cancer cell lines and animal models.
  • Clinical trial data analysis (Phase 1a, 1b, 2).
Keywords:
A6CD44CLLHAmetastasisocularrecurrenceresistant

More Related Videos

Murine Model of CD40-activation of B cells
12:24

Murine Model of CD40-activation of B cells

Published on: March 5, 2010

13.4K
Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

9.7K

Related Experiment Videos

Last Updated: Apr 15, 2026

Use of Single Chain MHC Technology to Investigate Co-agonism in Human CD8+ T Cell Activation
12:09

Use of Single Chain MHC Technology to Investigate Co-agonism in Human CD8+ T Cell Activation

Published on: February 28, 2019

10.4K
Murine Model of CD40-activation of B cells
12:24

Murine Model of CD40-activation of B cells

Published on: March 5, 2010

13.4K
Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

9.7K

Main Results:

  • A6 inhibits tumor cell migration, invasion, and metastasis by binding to CD44.
  • A6 demonstrates efficacy and safety in clinical trials for various conditions.
  • A6 shows therapeutic potential in diabetic retinopathy and age-related macular degeneration models.
  • A6 exhibits direct cytotoxicity towards specific leukemia cells.

Conclusions:

  • A6 is a promising therapeutic agent targeting the HA-CD44 pathway.
  • A6 offers a novel strategy for treating cancer and other diseases with a favorable safety profile.
  • Further research into A6's mechanisms and applications is warranted.